Abstract
Whereas docking screens have emerged as the most practical way to use protein structure for ligand discovery, an inconsistent track record raises questions about how well docking actually works. In its favor, a growing number of publications report the successful discovery of new ligands, often supported by experimental affinity data and controls for artifacts. Few reports, however, actually test the underlying structural hypotheses that docking makes. To be successful and not just lucky, prospective docking must not only rank a true ligand among the top scoring compounds, it must also correctly orient the ligand so the score it receives is biophysically sound. If the correct binding pose is not predicted, a skeptic might well infer that the discovery was serendipitous. Surveying over 15 years of the docking literature, we were surprised to discover how rarely sufficient evidence is presented to establish whether docking actually worked for the right reasons. The paucity of experimental tests of theoretically predicted poses undermines confidence in a technique that has otherwise become widely accepted. Of course, solving a crystal structure is not always possible, and even when it is, it can be a lot of work, and is not readily accessible to all groups. Even when a structure can be determined, investigators may prefer to gloss over an erroneous structural prediction to better focus on their discovery. Still, the absence of a direct test of theory by experiment is a loss for method developers seeking to understand and improve docking methods. We hope this review will motivate investigators to solve structures and compare them with their predictions whenever possible, to advance the field.
Keywords: Virtual screening, ligand discovery
Current Topics in Medicinal Chemistry
Title: Docking Screens: Right for the Right Reasons?
Volume: 9 Issue: 9
Author(s): Peter Kolb and John J. Irwin
Affiliation:
Keywords: Virtual screening, ligand discovery
Abstract: Whereas docking screens have emerged as the most practical way to use protein structure for ligand discovery, an inconsistent track record raises questions about how well docking actually works. In its favor, a growing number of publications report the successful discovery of new ligands, often supported by experimental affinity data and controls for artifacts. Few reports, however, actually test the underlying structural hypotheses that docking makes. To be successful and not just lucky, prospective docking must not only rank a true ligand among the top scoring compounds, it must also correctly orient the ligand so the score it receives is biophysically sound. If the correct binding pose is not predicted, a skeptic might well infer that the discovery was serendipitous. Surveying over 15 years of the docking literature, we were surprised to discover how rarely sufficient evidence is presented to establish whether docking actually worked for the right reasons. The paucity of experimental tests of theoretically predicted poses undermines confidence in a technique that has otherwise become widely accepted. Of course, solving a crystal structure is not always possible, and even when it is, it can be a lot of work, and is not readily accessible to all groups. Even when a structure can be determined, investigators may prefer to gloss over an erroneous structural prediction to better focus on their discovery. Still, the absence of a direct test of theory by experiment is a loss for method developers seeking to understand and improve docking methods. We hope this review will motivate investigators to solve structures and compare them with their predictions whenever possible, to advance the field.
Export Options
About this article
Cite this article as:
Kolb Peter and Irwin J. John, Docking Screens: Right for the Right Reasons?, Current Topics in Medicinal Chemistry 2009; 9 (9) . https://dx.doi.org/10.2174/156802609789207091
DOI https://dx.doi.org/10.2174/156802609789207091 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Yin and Yang of Polyphenols in Cancer Prevention: A Short Review
Anti-Cancer Agents in Medicinal Chemistry Computational Approaches to Model Ligand Selectivity in Drug Design
Current Topics in Medicinal Chemistry The Peripheral Anionic Site of Acetylcholinesterase: Structure, Functions and Potential Role in Rational Drug Design
Current Pharmaceutical Design Chromosomal Micro-aberration in a Saudi Family with Juvenile Myoclonic Epilepsy
CNS & Neurological Disorders - Drug Targets Growth Factors and Astrocytes Metabolism: Possible Roles for Platelet Derived Growth Factor
Medicinal Chemistry Melatonin Effects in REM Sleep Behavior Disorder Associated with Obstructive Sleep Apnea Syndrome: A Case Series
Current Alzheimer Research Human Umbilical Cord Stem Cell Xenografts Improve Cognitive Decline and Reduce the Amyloid Burden in a Mouse Model of Alzheimer's Disease
Current Alzheimer Research Neprilysin and Amyloid Beta Peptide Degradation
Current Alzheimer Research Functional Connectivity Hubs Could Serve as a Potential Biomarker in Alzheimer’s Disease: A Reproducible Study
Current Alzheimer Research Shikimate Kinase (EC 2.7.1.71) from Mycobacterium tuberculosis: Kinetics and Structural Dynamics of a Potential Molecular Target for Drug Development
Current Medicinal Chemistry Behavioral Pharmacology of Cannabinoids with a Focus on Preclinical Models for Studying Reinforcing and Dependence-Producing Properties
Current Drug Abuse Reviews Current Advances on Different Kinases Involved in Tau Phosphorylation, and Implications in Alzheimers Disease and Tauopathies
Current Alzheimer Research Antioxidant Food Supplements and Obesity-Related Inflammation
Current Medicinal Chemistry Emotions and the Body
Central Nervous System Agents in Medicinal Chemistry Can Trehalose Prevent Neurodegeneration? Insights from Experimental Studies
Current Drug Targets ROCK in CNS: Different Roles of Isoforms and Therapeutic Target for Neurodegenerative Disorders
Current Drug Targets Functional Connectivity in a Rat Model of Alzheimer's Disease During a Working Memory Task
Current Alzheimer Research Early Development of Symptomatic Drugs in AD: A Systematic Review of the Use of Biomarkers
CNS & Neurological Disorders - Drug Targets Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective
Current Neuropharmacology Late-Onset Glycogen Storage Disease Type 2
Current Molecular Medicine